Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 821-824

  Costedoat Chalumeau, Nathalie ^a   Amoura, Zahir ^a   Hulot, Jean Sébastien ^a   Aymard, Guy ^a   Leroux, Gaëlle ^a   Marra, Donata ^a   Lechat, Philippe ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING;

ADULT; ANTIRHEUMATIC AGENTS; ATTITUDE TO HEALTH; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; SEVERITY OF ILLNESS INDEX;

EID: 34249779535     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067835     Document Type: Article

References (15)

1. Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med 2005;353:487-97.
2. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
3. Uribe AG, Alarcon GS, Sanchez ML, McGwin G Jr, Sandoval R, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum 2004;51:258-63.
4. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002;47:630-8.
5. Mirotznik J, Ginzler E, Zagon G, Baptiste A. Using the health belief model to explain clinic appointment-keeping for the management of a chronic disease condition. J Community Health 1998;23:195-210.
6. Gladman DD, Koh DR, Urowitz MB, Farewell VT. Lost-to-follow-up study in systemic lupus erythematosus (SLE). Lupus 2000;9:363-7.
7. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000;9:601-6.
8. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
9. Ng HJ, Crowther MA. Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review. Am J Geriatr Pharmacother 2006;4:75-7.
10. Chapman JR. Compliance: the patient, the doctor, and the medication? Transplantation 2004;77:782-6.
11. Rudd P, Lenert L. Pharmacokinetics as an aid to optimising compliance with medications. Clin Pharmacokinet 1995;28:1-6.
12. Dusing R, Lottermoser K, Mengden T. Compliance with drug therapy - new answers to an old question. Nephrol Dial Transplant 2001;16:1317-21.
13. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90.
14. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
15. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.